White Market Drugs

White Market Drugs
Author: David Herzberg
Publisher: University of Chicago Press
Total Pages: 372
Release: 2020-10-23
Genre: History
ISBN: 022673191X

The contemporary opioid crisis is widely seen as new and unprecedented. Not so. It is merely the latest in a long series of drug crises stretching back over a century. In White Market Drugs, David Herzberg explores these crises and the drugs that fueled them, from Bayer’s Heroin to Purdue’s OxyContin and all the drugs in between: barbiturate “goof balls,” amphetamine “thrill pills,” the “love drug” Quaalude, and more. As Herzberg argues, the vast majority of American experiences with drugs and addiction have taken place within what he calls “white markets,” where legal drugs called medicines are sold to a largely white clientele. These markets are widely acknowledged but no one has explained how they became so central to the medical system in a nation famous for its “drug wars”—until now. Drawing from federal, state, industry, and medical archives alongside a wealth of published sources, Herzberg re-connects America’s divided drug history, telling the whole story for the first time. He reveals that the driving question for policymakers has never been how to prohibit the use of addictive drugs, but how to ensure their availability in medical contexts, where profitability often outweighs public safety. Access to white markets was thus a double-edged sword for socially privileged consumers, even as communities of color faced exclusion and punitive drug prohibition. To counter this no-win setup, Herzberg advocates for a consumer protection approach that robustly regulates all drug markets to minimize risks while maintaining safe, reliable access (and treatment) for people with addiction. Accomplishing this requires rethinking a drug/medicine divide born a century ago that, unlike most policies of that racially segregated era, has somehow survived relatively unscathed into the twenty-first century. By showing how the twenty-first-century opioid crisis is only the most recent in a long history of similar crises of addiction to pharmaceuticals, Herzberg forces us to rethink our most basic ideas about drug policy and addiction itself—ideas that have been failing us catastrophically for over a century.

County Lines

County Lines
Author: Robert McLean
Publisher: Springer Nature
Total Pages: 95
Release: 2019-11-15
Genre: Social Science
ISBN: 3030333620

This brief sheds light on evolving drug markets and the county lines phenomenon in the British context. Drawing upon empirical research gathered in the field between 2012-2019 across two sites, Scotland’s West Coast and Merseyside in England, this book adopts a grounded approach to the drug supply model, detailing how drugs are purchased, sold and distributed at every level of the supply chain at both sites. The authors conducted interviews with practitioners, offenders, ex-offenders and those members of the general public most effected by organised crime. The research explores how drug markets have continued to evolve, accumulating in the phenomenon that is county lines. It explores how such behavior has gradually become ever more intertwined with other forms of organised criminal activity. Useful for researchers, policy makers, and law enforcement officials, this brief recommends a rethinking of current reactive policing strategies.

Understanding the Demand for Illegal Drugs

Understanding the Demand for Illegal Drugs
Author: National Research Council
Publisher: National Academies Press
Total Pages: 124
Release: 2010-10-23
Genre: Law
ISBN: 0309159342

Despite efforts to reduce drug consumption in the United States over the past 35 years, drugs are just as cheap and available as they have ever been. Cocaine, heroin, and methamphetamines continue to cause great harm in the country, particularly in minority communities in the major cities. Marijuana use remains a part of adolescent development for about half of the country's young people, although there is controversy about the extent of its harm. Given the persistence of drug demand in the face of lengthy and expensive efforts to control the markets, the National Institute of Justice asked the National Research Council to undertake a study of current research on the demand for drugs in order to help better focus national efforts to reduce that demand. This study complements the 2003 book, Informing America's Policy on Illegal Drugs by giving more attention to the sources of demand and assessing the potential of demand-side interventions to make a substantial difference to the nation's drug problems. Understanding the Demand for Illegal Drugs therefore focuses tightly on demand models in the field of economics and evaluates the data needs for advancing this relatively undeveloped area of investigation.

The Oxford Handbook of Organized Crime

The Oxford Handbook of Organized Crime
Author: Letizia Paoli
Publisher: Oxford Handbooks
Total Pages: 713
Release: 2014
Genre: Law
ISBN: 019973044X

This handbook explores organized crime, which it divides into two main concepts and types: the first is a set of stable organizations illegal per se or whose members systematically engage in crime, and the second is a set of serious criminal activities that are typically carried out for monetary gain.

World Drug Report 2019

World Drug Report 2019
Author: United Nations Office on Drugs and Crime
Publisher:
Total Pages: 0
Release: 1901
Genre:
ISBN: 9789210041744

The 2019 World Drug Report will include an updated overview of recent trends on production, trafficking and consumption of key illicit drugs. The Report contains a global overview of the baseline data and estimates on drug demand and supply and provides the reference point for information on the drug situation worldwide.

Drug Wars

Drug Wars
Author: Robin Feldman
Publisher: Cambridge University Press
Total Pages: 165
Release: 2017-06-09
Genre: Law
ISBN: 131673949X

While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs.

Pain Management and the Opioid Epidemic

Pain Management and the Opioid Epidemic
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
Total Pages: 483
Release: 2017-09-28
Genre: Medical
ISBN: 0309459575

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.